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Background: Cellular plasticity confers cancer cells the ability to adapt to microenvironmental changes, a
fundamental requirement for tumour progression and metastasis. The epithelial to mesenchymal transition (EMT) is
a transcriptional programme associated with increased cell motility and stemness. Besides EMT, the mesenchymal
to amoeboid transition (MAT) has been described during tumour progression but to date, little is known about its
transcriptional control and involvement in stemness. The aim of this manuscript is to investigate (i) the
transcriptional profile associated with the MAT programme and (ii) to study whether MAT acquisition in melanoma
cancer cells correlates with clonogenic potential to promote tumour growth.
Results: By using a multidisciplinary approach, we identified four different treatments able to induce MAT in
melanoma cells: EphA2 overexpression, Rac1 functional inhibition using its RacN17 dominant negative mutant,
stimulation with Ilomastat or treatment with the RhoA activator Calpeptin. First, gene expression profiling identified
the transcriptional pathways associated with MAT, independently of the stimulus that induces the MAT programme.
Notably, gene sets associated with the repression of mesenchymal traits, decrease in the secretion of extracellular
matrix components as well as increase of cellular stemness positively correlate with MAT. Second, the link between
MAT and stemness has been investigated in vitro by analysing stemness markers and clonogenic potential of
melanoma cells undergoing MAT. Finally, the link between MAT inducing treatments and tumour initiating
capability has been validated in vivo.
Conclusion: Taken together, our results demonstrate that MAT programme in melanoma is characterised by
increased stemness and clonogenic features of cancer cells, thus sustaining tumour progression. Furthermore, these
data suggest that stemness is not an exclusive feature of cells undergoing EMT, but more generally is associated
with an increase in cellular plasticity of cancer cells.
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Plasticity in cell motility is a key prerequisite for the meta-
static dissemination of tumour cells. Indeed, cancer cells
may achieve different types of cell motility, including mes-
enchymal, collective, and amoeboid styles. Thus, by shift-
ing between different motility styles, migrating cells can
adapt to environmental changes and matrix stiffness to* Correspondence: paola.chiarugi@unifi.it
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unless otherwise stated.elude anticancer treatments, which represents a major
challenge for developing strategies aimed at blocking the
dissemination of cancer cells [1-3]. Mesenchymal motil-
ity depends on extra-cellular matrix (ECM) proteolysis
through production of matrix metalloproteinases (MMPs).
It is characterised by activation of Rac1 at the leading edge
of the cell, and inhibition of RhoA GTPase [3], confer-
ring to migrating cells an elongated and polarized cell
morphology. Conversely, amoeboid motility is charac-
terised by squeezing movements that allow cancer cells
to glide through matrix barriers, without the use of
MMPs and integrin engagement. Amoeboid movement
is characterised by a rounded morphology, high Rho
kinase signalling to drive elevated levels of actomyosinLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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but failed to have effect on tumour metastasis [4], prob-
ably due to the plasticity of tumour cells and their abil-
ity to invade in an amoeboid manner in the absence of
protease activity [5].
Previous data report that the epithelial mesenchymal
transition (EMT) is promoted by the induction of a tran-
scriptional programme that has been associated with the
activation of several key transcriptions factors, including
Snail (SNAI1), Slug (SNAI2), Twist and ZEB-1/2. This
transcriptional programme ultimately leads to the dis-
ruption of adherens junctions, activation of polarized
cell motility and increased degradation of ECM through
secretion of MMPs [6-8]. In addition to EMT, a second
type of motility shift has been described as essential in
tumour progression, i.e., mesenchymal amoeboid transi-
tion (MAT) [9]. MAT can be induced in cancer cells by
pharmacological inhibition of integrin function or MMP
activity, by p53 or p27 deficiency [10,11], as well as
through the activation or re-expression of EphA2
[5,12-14]. Although MAT confers a clear advantage to
metastatic processes, very little is known about the mo-
lecular events that promote this motility shift [12,13,15].
Mammary epithelial cells undergoing EMT are
endowed with stem-cell features, generating anchorage-
independent mammospheres, soft agar colonies, and tu-
mours [16]. Accordingly, we previously reported that the
contact with cancer associated fibroblasts promotes
EMT in the neighbouring prostate carcinoma cells,
allowing them to acquire stem cell traits [17]. On the
other hand, nothing is known to our knowledge, about a
possible transcriptional regulation of amoeboid motility.
However, also for MAT we have recently discovered a
possible link with stemness. Indeed, in prostate cancer
and glioblastoma, EphA2 expression, which induces an
amoeboid motility, has been associated with achieve-
ment of stemness markers, increased clonogenic poten-
tial and tumour growth [15,18].
Melanoma cells are endowed with great plasticity in mi-
gration. Indeed, we have recently demonstrated that mel-
anoma cells are able to shift between mesenchymal and
amoeboid motility: melanoma cells move mesenchymally
in response to pro-inflammatory cytokines, whereas after
re-expression of embryonic EphA2 receptor, they achieve
an amoeboid motility style giving rise to successful metas-
tatisation [13]. Furthermore, Sanz-Moreno et al. showed
that A375M2 primary melanoma cells can switch ad hoc
between mesenchymal and amoeboid motility [19]. Fur-
thermore, the same authors have recently demonstrated
that treatment of melanoma cells with the Src inhibitor
dasatinib results in a switch from mesenchymal migration
to ROCK-dependent amoeboid invasion, confirming, once
again, that cancer cell migratory capabilities could be
blocked only by a combination of different treatmentseffective in the inhibition of both mesenchymal and
amoeboid motility styles [20]. To confirm that cancer cells
often undergo plasticity in cell motility, the opposite
transition has been also described: the group of Mar-
shall demonstrated that A375 M2 melanoma cells move
in a rounded, amoeboid manner on top of or through
collagen matrices due to JAK1-dependent MLC2 phos-
phorylation, whereas silencing of JAK1 induces a reduc-
tion in the acto-myosin contractility and the acquisition
of an elongated morphology [21]. Moreover, the block
of p53 function is sufficient to convert melanoma cells
from an elongated motility style to a rounded locomo-
tion, suggesting that such switch would favour the dis-
semination of p53-defective tumour cells by increasing
their invasiveness [11].
In this light, the aim of our work is to investigate the
regulation of mesenchymal to amoeboid transition in-
duced in human melanoma cells by different stimuli and
the possible link with the acquisition of clonogenic po-
tential in order to sustain tumour growth in response to
changes in microenvironmental conditions.
Results and discussion
EphA2 or RacN17 overexpression, treatment with Rho
activator or ilomastat induces an amoeboid motility style
in Hs294T melanoma cells
Previous studies from our laboratory demonstrated that
overexpression of EphA2 in murine melanoma cells con-
verts their migration style from mesenchymal to
amoeboid like, thus conferring a cell plasticity in tumour
invasiveness [13]. We now investigate the induction of
an amoeboid motility style in human melanoma Hs294T
cells following EphA2 overexpression and compare to
amoeboid motility induced by RacN17 overexpression,
treatment with the Rho activator Calpeptin or the
MMPs inhibitor Ilomastat. We first analysed the activa-
tion level of RhoA and Rac1 small GTPases, as both
RhoA activation and Rac1 inhibition have been corre-
lated with a proteolysis independent motility style [12].
As shown in Figure 1A all these treatments are able to
activate RhoA and to inhibit Rac1, thus suggesting a
possible induction of an amoeboid motility in human
melanoma cells. In addition, following all the aforemen-
tioned treatments, melanoma cells undergo cell round-
ing, a typical prerequisite for the acquisition of an
amoeboid motility (Figure 1B). The confirmation that
these cells undergo a real MAT emerges from the ana-
lysis of cell morphology in 3D collagen matrices, using
confocal fluorescence reflection microscopy. As shown
in Figure 1C all these treatments cause the acquisition of
a round-shaped squeezing morphology while control
cells maintain an elongated profile and establish contacts
with collagen fibers. In addition, to exclude that the in-
duction of the amoeboid morphology could be toxic for
Figure 1 (See legend on next page.)
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Figure 1 EphA2 or RacN17 overexpression, treatment with Rho activator or ilomastat induce RhoA activation and Rac1 inhibition and
acquisition of a rounded morphology. A) 106 Hs294T, EphA2 or RacN17 transfected cells were serum starved for 48 h, for Ilomastat treatment
cells were serum starved for 48 h in the presence of 50 μmol/L Ilomastat, for Rho activation treatment cells were serum starved for 48 h and then
stimulated with 1 U/ml Calpeptin for 2 h at 37°C. After treatments, RhoA-GTP and Rac1-GTP were analysed by pull-down assay from cell lysates.
The total amount of RhoA and Rac1 were quantified by anti-Rho and anti-Rac1 immunoblot. An anti-actin antibody was used to ensure equal
protein loading. The bar graphs obtained from densitometry analysis of triplicate experiments are shown. Student t-test, *p < 0.001 treatments vs
control, #p < 0.005 treatments vs control. B) Cells were treated as in A), photographs were taken and a representative image of their morphology
is shown. Bar, 20 μm. C) Cell treated as in A) were labeled with CFSE and then incubated in three-dimensional collagen lattice. Cell morphology
was monitored by confocal fluorescence-reflection microscopy. Photographs are representative of several randomly chosen fields. Bar, 20 μm.
D) Cells were treated as in A). The percentage of apoptotic cells was evaluated using the Muse™ Annexin V & Dead Cell kit. The results are
representative of three experiments with similar results. Student t-test, *p < 0.01 EphA2 vs control, #p < 0.05 RacN17 vs control.
Taddei et al. Cell Communication and Signaling 2014, 12:24 Page 4 of 12
http://www.biosignaling.com/content/12/1/24cells, we performed a cell viability assay. Figure 1D shows
that none of the aforementioned treatments interfere with
cell viability. To further investigate the motility of EphA2
or RacN17 overexpressing cells, as well as cells treated
with Rho activator or Ilomastat, we tested their invasive
abilities to cross a Matrigel barrier in the presence or ab-
sence of the MMPs inhibitor, Ilomastat. Indeed, sensitivity
to protease inhibition of invasive ability of cells has been
widely used as a mesenchymal/amoeboid discriminant test
[13,15]. As shown in Figure 2A, control cells behaviour is
highly influenced by the presence of Ilomastat. Con-
versely, cells exposed to MAT inducing treatments are
completely unaffected by the presence of Ilomastat, sug-
gesting that they preferentially use a MMPs-independent
motility (Figure 2A). Indeed, the acquisition of an
amoeboid motility style has been confirmed by MMPs
analysis by gelatine zymography, which actually reveals
both a decrease in expression and activation of MMP2 in
cells overexpressing EphA2, RacN17 or treated with Rho
activator or Ilomastat (Figure 2B). Overall, these data con-
firm that Hs294T melanoma cells undergo a clear MAT
in response to all treatments used, highlighting the great
plasticity in cell motility of these tumour cells.
EphA2 overexpression, treatment with Rho activator or
ilomastat activate common signalling pathways to
achieve amoeboid motility
It is now well established that EMT is an epigenetic
programme, mainly regulated at a transcriptional level,
involving several factors, such as Snail, Slug, Twist, Goo-
secoid, ZEB1, and SIP1 [22,23]. We next investigated
whether MAT induction displays common transcrip-
tional traits independently of the stimuli that activate
the MAT programme by gene expression profiling on
Hs294T cells overexpressing EphA2, or treated with Ilo-
mastat or the Rho activator Calpeptin. A class compari-
son was performed between treated cells and controls,
ranking all genes according to Student t-test statistics.
Gene set enrichment analysis (GSEA) [24] was applied
to such ranked list to identify gene sets directly or in-
versely associated with MAT inducing treatments (i.e.EphA2, Ilomastat and Rho activator). The GSEA analysis
revealed that MAT induction, independently of the
stimulus that has activated the MAT programme, associ-
ates with several biofunctions represented by multiple
gene sets, as reported in Table 1 and Additional file 1:
Table S1. Notably, GSEA analysis revealed that the activation
of the MAT programme associates with the repression of
features that are characteristics of cell undergoing EMT as
shown by a negative correlation with ANASTOSIOU_
CANCER_MESENCHYMAL_TRANSITION_SIGNATURE
gene set. However, a positive correlation was found with
gene sets that are related to TGF-β, a well-known EMT
inducer, targets of the EMT activator ZEB1 and with tar-
gets that are down regulated by E-cadherin expression
(Table 1, epithelial mesenchymal transition). This let us
speculate that MAT programme is not just a phenomenon
that recapitulates the mesenchymal-to-epithelial transition
(MET). The ability to acquire an amoeboid motility con-
fers the cancer cells characteristics that are both of mesen-
chymal and epithelial cells and therefore are features of
aggressive cancer cells with high plasticity. In keeping with
the fact that MAT is significantly regulated by RhoA acti-
vation [12], we observed a positive correlation with the
BERENJENO_TRANSFORMED_BY_RHOA_UP gene sets
(Table 1, Rho). Based on our data, we suggest a model
where EMT and MAT are different status that a cancer
cell can display during cancer progression. Particularly,
the EMT has to be at least partially repressed to allow the
cell to enter into the MAT status, suggesting a hierarchy
between EMT and MAT where MAT is a consecutive
event of the EMT programme. Crucially, this may explain
why clinical trials aimed at blocking EMT using anti pro-
teolytic agents did not succeed [4,5].
It is well known that MAT is promoted in looser
matrices and is independent on contacts between cells
and ECM [25-27]. In agreement with this rearrangement
of the ECM, many of the gene sets identified positively
correlate with a decrease in the secretion of ECM com-
ponents, e.g. collagen, and with a reduction of contacts
between cellular receptors (Table 1, extracellular matrix
gene sets). These data suggest that MAT transcriptional
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Figure 2 Cells overexpressing EphA2 or RacN17, treated with Rho activator or ilomastat acquire an amoeboid- MMP-independent
motility style. A) Hs294T, EphA2 or RacN17 transfected cells were serum starved for 48 h, for Ilomastat treatment cells were serum starved for
48 h in the presence of 50 μmol/L Ilomastat, for Rho activation treatment cells were serum starved for 48 h and then stimulated with 1 U/ml
Calpeptin for 2 h at 37°C. Then, 6×104 cells were seeded into the upper compartment of Boyden chamber with or without 50 μM Ilomastat. Cells
were allowed to migrate through the filter coated with Matrigel toward the lower compartment filled with complete medium. Cell invasion was
evaluated after Diff-Quick staining by counting cells in six randomly chosen fields. The results are representative of three experiments with similar
results. Student t-test, *p < 0.001 ILO treatment vs untreated, #p < 0.05 ILO treatment vs untreated. B) Analysis of MMP activity. Media from
confluent monolayers of cells treated as in A) were collected and analysed by gelatine zymography. The clear bands represent areas of gelatinase
activity. The results shown are representative of four experiments.
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ness that supports amoeboid motility style. In fact,
amoeboid moving cells that need to squeeze within
ECM fibres do not rely on proteolytic degradation of ro-
bust ECM and would certainly benefit from the release
of cell adhesion bindings, from loosen and relax ECM
stiffness, as well as from changes in ECM composition.
Although we observed that EMT is impaired during
MAT, some features of EMT, emerged also from GSEA
analysis, are maintained in cells moving with amoeboid
motility. Indeed, we observe that MAT inducers treat-
ment of Hs294T cells positively associates with gene
sets involved in anoikis resistance and cell survivalsuch as Epidermal Growth Factor (EGF) and Neuregu-
lin 1 (NRG1) (Table 1, EGF signalling). Anoikis resist-
ance is an essential requirement for a cancer cell that
leaves the primary site to survive in the blood stream
in order to metastasize to distant sites. This ability is
even more crucial for a cell that is moving with amoeboid
motility, i.e. independently of integrin engagement [12]. A
positive correlation of MAT inducers treatment of melan-
oma cells with EGF signalling in cells moving with
amoeboid motility is in keeping with previous studies de-
scribing EGFR activation during protection from anoikis
[28]. Indeed, cells can prevent anoikis through the oxida-
tion/activation of the tyrosine kinase Src, thus granting
Table 1 GSEA analysis: gene sets significantly correlated with MAT-inducing treatments
Biological category Gene set Size NES FDR(q-value) Enriched in
EGF signalling
NAGASHIMA_EGF_SIGNALING_UP 57 2.773 0.000 Treated
NAGASHIMA_NRG1_SIGNALING_UP 169 2.826 0.000 Treated
ZWANG_CLASS1_TRANSIENTLY_INDUCED_BY_EGF 497 2.455 0.000 Treated
AMIT_EGF_RESPONSE_60_HELA 43 2.305 0.000 Treated
ZWANG_CLASS3_TRANSIENTLY_INDUCED_BY_EGF 217 2.263 0.000 Treated
AMIT_EGF_RESPONSE_240_HELA 59 2.177 0.001 Treated
AMIT_EGF_RESPONSE_120_HELA 67 2.098 0.002 Treated
AMIT_EGF_RESPONSE_480_MCF10A 42 2.034 0.004 Treated
AMIT_EGF_RESPONSE_40_HELA 42 1.972 0.007 Treated
Epithelial-mesenchymal
transition
ANASTASSIOU_CANCER_MESENCHYMAL_TRANSITION_SIGNATURE 63 −2.348 0.000 Control
AIGNER_ZEB1_TARGETS 34 −2.148 0.002 Control
ONDER_CDH1_TARGETS_1_DN 166 2.339 0.000 Treated
KARLSSON_TGFB1_TARGETS_UP 124 2.426 0.000 Treated
PLASARI_TGFB1_TARGETS_1HR_UP 34 2.296 0.000 Treated
Extracellular matrix
REACTOME_COLLAGEN_FORMATION 57 −2.547 0.000 Control
PROTEINACEOUS_EXTRACELLULAR_MATRIX 95 −2.224 0.001 Control
KEGG_ECM_RECEPTOR_INTERACTION 84 −2.264 0.001 Control
PID_INTEGRIN1_PATHWAY 66 −2.200 0.001 Control
EXTRACELLULAR_MATRIX_PART 54 −2.203 0.001 Control
KEGG_CELL_ADHESION_MOLECULES_CAMS 130 −2.127 0.002 Control
EXTRACELLULAR_MATRIX 96 −2.108 0.002 Control
REACTOME_EXTRACELL_MATRIX_ORGANIZATION 83 −2.063 0.004 Control
COLLAGEN 22 −1.994 0.007 Control
HOXA5 pathway CHEN_HOXA5_TARGETS_9HR_UP 216 3.745 0.000 Treated
HDAC
SENESE_HDAC1_AND_HDAC2_TARGETS_UP 227 2.790 0.000 Treated
SENESE_HDAC1_TARGETS_UP 429 2.968 0.000 Treated
SENESE_HDAC2_TARGETS_UP 110 2.525 0.000 Treated
SENESE_HDAC3_TARGETS_UP 471 2.281 0.000 Treated
Stemness
NGUYEN_NOTCH1_TARGETS_DN 85 2.258 0.000 Treated
RAMALHO_STEMNESS_UP 201 2.089 0.002 Treated
Rho metabolic
process
BERENJENO_TRANSFORMED_BY_RHOA_DN 381 −1.951 0.010 Control
CELLULAR_PROTEIN_CATABOLIC_PROCESS 56 2.164 0.001 Treated
REACTOME_DEADENYLATION_OF_MRNA 19 2.062 0.003 Treated
PROTEIN_CATABOLIC_PROCESS 64 2.058 0.003 Treated
MRNA_METABOLIC_PROCESS 83 1.940 0.009 Treated
OXIDOREDUCTASE_ACTIVITY 281 −2.123 0.002 Control
OXIDOREDUCTASE_ACTIVITY_GO_0016616 56 −1.991 0.007 Control
OXIDOREDUCTASE_ACTIVITY_ACTING_ON_CH_OH_GROUP_OF_DONORS 62 −1.951 0.010 Control
Metastasis CHANDRAN_METASTASIS_UP 197 1.975 0.007 Treated
CHANDRAN_METASTASIS_TOP50_UP 37 1.967 0.007 Treated
PEDERSEN_METASTASIS_BY_ERBB2_ISOFORM_1 45 2.300 0.000 Treated
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dependent and ligand-independent phosphorylation of
EGFR, which leads to Bim degradation [28].
It is now well established that EMT correlates with the
achievement of stemness traits in multiple cancer models
[16,17]. In addition, we have recently demonstrated that
in prostate carcinoma cells, EphA2 silencing induces the
loss of amoeboid motility style as well as a decrease in
stem cell markers, thus suggesting that also MAT can be
related to stemness and tumour growth [15]. In keeping
with these observations, we observed that MAT inducing
treatments in melanoma cells positively correlate with
stemness gene sets (Table 1, stemness), suggesting that
the achievement of stemness traits is not limited to EMT
programme, but is a more general feature associated with
the plasticity of tumour cell motility. These data suggest
that, although EMT is a transcriptional programme lead-
ing to achievement of stemness traits [16,17,29], the add-
itional shift occurring in cancer cells undergoing MAT
contributes and enhances these stem-like features, further
promoting the spread of metastases. In keeping, GSEA
analysis revealed that metastases associated gene sets posi-
tively correlates with MAT inducers treatment (Table 1,
metastasis). Furthermore, following MAT induction in
Hs294T cells, we observed (i) a positive correlation with
gene sets related to protein catabolism and (ii) a negative
correlation with anabolic processes (Table 1, metabolic
process). The increase in catabolic processes, likely con-
nected to autophagy and leading cancer cells to self-
sustain their metabolism during starvation, is a very com-
mon feature of cancer cells. Indeed, several tumours are
often exposed to oxygen or nutrient deprivation, owing to
mass overgrowth and insufficient angiogenesis [30]. En-
gagement of self-cannibalism and autophagic strategies
have been indicated as protective against environmental
stress, nutrient deprivation or chemotherapy treatment
[31-33]. Metabolic deregulation of cancer cells during
tumour progression has now attracted the interest of on-
cologists and is now a new Hallmark of Cancer [34], but
there are very few data describing the metabolic repro-
gramming of cancer cells upon changes in their motility
styles to compare them with the output of our GSEA ana-
lysis. Interestingly, EMT has been correlated with en-
hancement of anabolic processes, increase in cell biomass
and therefore in cancer growth. While MAT appears an
exacerbation of EMT programme for several aspects (e.g.
activation of survival pathways and achievement of stem-
like traits), the metabolic features of EMT or MAT under-
going cells appear to diverge.
Similarly to what observed in EMT, we suppose that
also for the MAT programme a typical transcriptional
profile could be identified. MAT inducing treatments
show a positive correlation with histone deacetylase
(HDAC) related gene sets (Table 1, HDAC), a feature ofchromatin rearrangement, thus suggesting that MAT in-
ducing treatments impact on gene transcriptional regula-
tion. Importantly, in all MAT inducing treatments we
found an important positive correlation with the HOXA5
controlled pathways (Table 1, HOXA5). HOXA5 is a tran-
scription factor with a crucial role during morphogenesis
and tumourigenesis [35]. Although it has not yet been in-
volved in MAT and studies on its role in control of motil-
ity are still at their infancy, HOXA5 has been implicated
in repression of EMT through regulation of ZEB1 or Snail
[36-38]. These indications are in keeping with our obser-
vation that MAT induces a repression of the mesenchymal
phenotype (Table 1, epithelial-mesenchymal transition).
MAT promotes an increase in stem cell markers,
self-renewal of melanoma cells, tumour growth in
nude mice
To further investigate the link between stemness and
MAT, we decided to analyse whether EphA2 or RacN17
overexpression, treatment with Rho activator or Iloma-
stat are able to further enhance the stemness of melan-
oma cells. Flow cytometry analysis of Hs294T cells
reveals that all treatments inducing MAT enhance ex-
pression of CD20 and CD133, established stemness
markers in melanoma (Figure 3A-B). In addition, qRT-
PCR analysis showed increased levels of known embry-
onic stem cell factors like KLF4, NANOG, SOX2 and
OCT4 which are involved in the maintenance of the un-
differentiated state of stem cells and in the stem cell
self-renewal [39,40] (Figure 3C-F). In keeping with the
increase of the stem cell markers, activation of MAT in-
creases the clonogenic potential of Hs294T cells,
assessed by melanospheres formation assay and P1 mela-
nospheres development (Figure 3G-H). The ability to
form melanospheres is in keeping with anchorage inde-
pendence and resistance to anoikis of Hs294T melan-
oma cells. We also confirm the link between MAT and
stemness in a different cellular system, i.e. PC3 prostate
carcinoma cells undergoing MAT in response to contact
with endothelial cells [41]. Again, in MAT undergoing
cells we observed an increase in stem cell markers, as
well as an increase of the clonogenic potential
(Additional file 2: Figure S1). These data confirm that
MAT can induce a stem cell phenotype in different
tumour types, independently of the MAT inducing
stimuli.
EphA2 expression is a common event during activation
of MAT. In keeping with this, both Ilomastat and Rho
activator induce EphA2 expression in melanoma cells
(Figure 4A). For this reason, between the different treat-
ments able to induce amoeboid motility, we selected
EphA2 overexpressing cells to perform in vivo experi-
ments. To test whether MAT could promote tumour
growth in vivo, we compared the tumour initiating
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Figure 3 Cells overexpressing EphA2 or RacN17, treated with Rho activator or ilomastat promote MAT and induce an increase in stem
cell markers and clonogenic potential. A-B) Hs294T, EphA2 or RacN17 transfected cells were serum starved for 48 h, for Ilomastat treatment
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stimulated with 1 U/ml Calpeptin for 2 h at 37°C. Cells were then analysed for expression of the cell-surface markers CD20 and CD133 by means
of cytometry. The CD20 or and CD133-positive populations were plotted. The results are representative of three experiments with similar results.
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mRNA expression level was analyzed by qRT-PCR. Results are representative of three experiments with similar results. Student t-test, *p < 0.005
treatments vs control. G) Representative images of clones obtained from cells treated as in A) after 10 days of culturing at clonal densities. Bar,
100 μm. Clones were photographed, counted and the mean ± SD of clones number/field is reported. H) P1 individual spheres, derived from
dissociated single melanospheres, were counted and the bar graphs obtained from triplicate experiments are shown. Student t-test, *p < 0.005.
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Taddei et al. Cell Communication and Signaling 2014, 12:24 Page 9 of 12
http://www.biosignaling.com/content/12/1/24capacities of control melanoma cells and EphA2 overex-
pressing cells after s.c. injection into SCID-bg/bg mice.
At lower concentration (103 cells) EphA2 influences the
rate of tumour growth and at higher concentration (104
cells) both the onset and the growth of tumour are in-
fluenced by EphA2 overexpression (Figure 4C-D), thus
demonstrating that the induction of MAT, in parallel
with an enrichment of stem cell traits in Hs294T melan-
oma cells, drives an increase in tumourigenesis.
Conclusion
In conclusion, MAT is likely to be an epigenetic invasive
programme, hierarchically succeeding EMT, which fur-
ther strengthens the stem-like and clonogenic features
of cancer cells. For this reason, before fixing the concept
that stemness is due to EMT engagement [16,17,23,29,36-38,
42,43], it should be more correct to correlate stemness
to enhanced plasticity in cells motility, a wider concept
including EMT and MAT. Pharmacological strategies
aimed at blocking only EMT are therefore destined to
collide with the enormous adaptive and plastic features
of cancer cells and should be revised by including MAT
as an additional target of anti metastatic treatments.Methods
Materials
Unless otherwise specified all reagents were obtained
from Sigma. Anti EphA2 antibodies were from Upstate
Biotechnology Inc. The invasion chambers were from
Corning Costar. The Matrigel Matrix, anti Rac1 antibody
were from RD System. Ilomastat was from Chemicon
International. RNeasy Plus Mini kit was from Qiagen.
Type I collagen, the FITC mouse anti human CD44
(clone G44-26) and PE mouse anti human CD24 (clone
ML5) antibodies were from BD Bioscience (San Jose,
CA, USA). CD133 and CD20 antibodies were from
Abcam. Anti mouse Alexa 488 antibody was from Mo-
lecular Probes. The Rho activator was from Cytoskeleton.
Magnetic Dynabeads CD31 for endothelial cell separation
was obtained from Invitrogen.
Cell culture and transfection
Hs294T human melanoma cells and prostate cancer cells
(PC3) were purchased from ATCC and cultured in
DMEM supplemented with 10% FCS at 37°C in 5% CO2
humidified atmosphere. Endothelial progenitor cells
(EPCs) have been isolated from human umbilical cord
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tured on gelatin 1% coated dishes in EGM-2 medium
(Lonza). Hs294T cells were transfected with RacN17 (a
dominant negative mutant of Rac1) or EphA2 constructs
using Lipofectamine 2000 (Invitrogen) according to
manifacturer’s instructions.
Analysis of cell morphology in 3D matrix
Cells were labeled by 5 μmol/L Cell Trace CFSE (Invitrogen)
for 30 min at 37°C. Cells were then detached by Accutase
(Sigma), washed and incorporated into 3-dimensional
(3D) collagen I lattice (1.67 mg/mL rat tail collagen I).
After 5 h, photographs were taken under confocal mi-
croscopy (Leica-SP5 system).
Cell viability assay
105 cells were detached using Accutase (Sigma) and sus-
pended with 100 μl of the Muse™ Annexin V & Dead Cell
Reagent (Millipore) according to manufacturer’s instruc-
tions. After 20 min, the percentage of apoptotic cells was
analyzed by the Muse™ Cell Analyzer (Millipore).
RhoA or Rac1 activity assay
Cells were directly lysed in RIPA buffer, the lysates were
clarified by centrifugation and RhoA-GTP or Rac-GTP
were quantified. Briefly, lysates were incubated with 10
μg Rhotekin-GST fusion protein (Becton Dickinson) or
p21 activated kinase (PAK)-GST fusion protein, both
absorbed on glutathione Sepharose beads for 1 h at 4°C.
Immunoreactive RhoA or Rac1 were then quantified by
western blot analysis. Lysates were normalised for RhoA
or Rac1 content by immunoblot.
Western blot analysis
1×106 cells were lysed for 20 min on ice in 500 μl of
complete radioimmunoprecipitation assay (RIPA) lysis
buffer [50 mM Tris–HCl (pH 7.5), 150 mM NaCl, 1%
NP40, 2 mM EGTA, 1 mM sodiumorthovanadate, 1 mM
phenylmethylsulfonylfluoride, 10 μg/ml aprotinin, 10 μg/
ml leupeptin]. Lysates were clarified by centrifuging, sep-
arated by SDS-PAGE, and transferred onto nitrocellu-
lose. The immunoblots were incubated in 3% bovine
serum albumin, 10 mM Tris–HCl (pH 7.5), 1 mM
EDTA and 0.1% Tween 20 for 1 h at room temperature
and were probed first with specific antibodies and then
with secondary antibodies.
Cell co-cultures
PC3 were cultured with EPCs (1:1 ratio) in EGM-2
serum-free medium for 48 h. PC3 cells alone were plated
as a control. At the end of the co-culture, cells were sep-
arated using magnetic Dynabeads CD31 (Invitrogen) ac-
cording to manufacturer’s instructions.Invasion assay
Cells were serum starved for 48 h and then 6×104
cells were seeded onto Matrigel-precoated Boyden
chamber (8 mm pore size, 6.5 mm diameter, 12.5 μg
Matrigel/filter) with or without 50 μM Ilomastat. In
the lower chamber, complete medium was added as
chemo attractant. Following 24 h of incubation, the in-
serts were removed and the non invading cells on the
upper surface were removed with a cotton swab. The
filters were then stained using the Diff-Quick kit (BD
Biosciences) and photographs of randomly chosen fields
are taken.Gelatin zymography
Serum free medium from monolayer of cells was col-
lected and 20 μl were added to sample buffer (SDS 0.4%,
2% glycerol, 10 mM Tris–HCl, pH 6.8, 0.001% bromphe-
nol blue). The sample were run on a 10% SDS gel con-
taining 0.1% gelatin. After electrophoresis the gel was
washed twice with 2.5% Triton X-100 and once with re-
action buffer (50 mM Tris–HCl, pH 7.5, 200 mM NaCl,
5 mM CaCl2). The gel was incubated over night at 37°C
with freshly added reaction buffer and stained with
Laemli Comassie blue solution. Areas of gelatinase activ-
ity appear as clear bands against a dark background.Gene expression profiling
Hs294T were serum starved for 48 h and in the presence
of 50 μmol/L Ilomastat or serum starved for 48 h and
treated with the Rho activator Calpeptin 1 U/ml for the
last 2 h of incubation. EphA2-overexpressing Hs294T cells
were serum starved for 48 h. Total RNA was isolated from
Hs294T cells using RNeasy Plus Mini kit (Qiagen). Dupli-
cate sample from 2 independent experiments were hybrid-
ized onto Human AffymetrixHuGene St 1.0 GeneChip
array (Affymetrix) by Microarray Unit Cogentech (Milan,
Italy). Data were normalised by RMA (Robust Multichip
Analysis) algorithm using the affy package of Bioconduc-
tor/R. Microarray data have been uploaded in GEO
(GSE52246). Class comparison between treated and con-
trols samples was performed using a moderated t-test as
implemented in the limma package of Bioconductor/R.
Gene set enrichment analysis was performed using the
GSEA v2.0 [24] on the pre-ranked gene list by applying the
t-test statistics as ranking criteria. Both C2 (canonical path-
ways and signatures from the literature) and C5 (gene
ontology terms) gene set collections from the MSigDB
database (http://www.broadinstitute.org/gsea/msigdb) were
tested for enrichment and gene sets with FDR < 1% were
considered significantly enriched. Several biofunctions, each
supported by multiple enriched gene sets were identified
and reported in Table 1 and a complete list of the gene sets
is reported in Additional file 1: Table S1.
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To determine the surface expression of CD20, CD133,
CD44 and CD24 106 cells were detached non-
enzymatically with 2.5 mM EDTA and incubated with
the antibodies according to manufacturer’s instructions
in PBS containing 1% BSA for 1 h at 4°C. After washing
with PBS/1% BSA cells were incubated with Alexa 488
labelled anti mouse antibodies for 30 min at 4°C. Upon
washing, a flow cytometer analysis was performed.
Real time RT-PCR
Total RNA from Hs294T melanoma cells was extracted
using RNeasy (Qiagen) according to the manufacturer
instructions. Strands of cDNA were synthesized using a
high capacity cDNA reverse transcription kit (Applied
Biosystem) using 1 μg of total RNA. For quantification
of mRNA expression, Real-Time PCR, using Power
SYBR green dye (Applied Biosystem) was done on a
7500 Fast Real Time PCR system (Applied Biosystem).
The primers were NANOG: 5′-ACCTTGGCTGCCGTCT
CTGG-3′ (forward), 5′-AGCAAAGCCTCCCAATCCCAA
ACA-3′ (reverse); KLF4: 5′-GCAGCCACCTGGCGAGTC
TG-3′ (forward), 5′-CCGCCAGCGGTTATTCGGGG-3′
(reverse); SOX2 5′-GAGCTTTGCAGGAAGTTTGC-3′
(forward), 5′-GCAAGAAGCCTCTCCTTGAA-3′ (reverse);
OCT4: 5′-TTTTGGTACCCCAGGCTATG-3′ (forward),
5′-GCAGGCACCTCAGTTTGAAT-3′ (reverse). Data
were normalized to those obtained with Glyceraldehyde-
3-phosphate deydrogenase primers. Results (mean ± SD)
are the mean of three different experiments.
Prostaspheres/melanospheres formation and
clonogenicity assay
Cells were detached using Accutase (Sigma). For prosta-
spheres and melanospheres formation, single cells were
plated at 150 cells/cm2 on low attachment 100 mm plate
(Corning) in DMEM/F12 (Invitrogen, Carlsbad, CA, USA)
supplemented with B27 and N2 (Invitrogen), 5 μg/ml in-
sulin, 20 ng/ml bFGF and 20 ng/ml EGF for prostaspheres
or supplemented with N2, 0.6% glucose, 20 μg/ml insulin,
10 ng/ml bFGF and 100 ng/ml EGF for melanospheres.
Cells were grown under these conditions for 10 days and
then prostaspheres and melanospheres were photo-
graphed. For the evaluation of self-renewal, a single mela-
nosphere was dissociated in single cells with Accutase,
and a diluition of one cell per well into 96-well low attach-
ment plates was performed in order to isolate individual
P1 melanospheres. Single-cell cloning was confirmed by
microscopic analysis, and single clones were counted.
In vivo experiments
Xenograft experiments were performed in agreement
with national guidelines and approved by the ethical
committee of Animal Welfare Office of Italian WorkMinistry and conform to the legal mandates and Italian
guidelines for the care and maintenance of laboratory
animals. 6–8 weeks old male SCID-bg/bg mice (Charles
River Laboratories International, Inc., Wilmington, MA,
USA) were injected subcutaneously (s.c.), both in the
right and left lateral flanks, with cells mixed in a 1:1 vol-
ume ratio with Matrigel, in a final volume of 200 μl. An-
imals were monitored, tumour size was measured by a
caliper and tumour volumes determined by the length
(L) and the width (W): V = (LW2)/2.
Additional files
Additional file 1: Table S1. GSEA analysis output. Gene Set Enrichment
Analysis was performed with C2 and C5 collections of gene sets as
described in the Methods section.
Additional file 2: Figure S1. MAT promotes stemness in prostate
cancer cells. A) PC3 cells were co-cultured or not with EPC for 48 h in
order to induce MAT, then photographs were taken, the arrow shows a
representative cell that has acquired a rounded morphology. Bar, 50 μm.
B) PC3 cells were treated as in A), after separation, PC3 cells were
analysed for expression of the cell-surface marker FITC-CD44 and
PE-CD24 and CD133 by means of cytometry. The CD44high/CD24lowor
CD133-positive populations were plotted. Results shown are
representative of three experiments. Student t-test, *p < 0.001 PC3 in
co-culture vs PC3 alone. C) Representative images of clones obtained
from PC3 cells or PC3 co-cultured with EPC after 20 days of culturing at
clonal densities. Bar, 100 μm.
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